Logo image of BHST

BIOHARVEST SCIENCES INC (BHST) Stock Fundamental Analysis

NASDAQ:BHST - Nasdaq - CA09076J2074 - Common Stock - Currency: USD

8.0999  +0.2 (+2.53%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BHST. BHST was compared to 35 industry peers in the Personal Care Products industry. Both the profitability and financial health of BHST have multiple concerns. BHST is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BHST has reported negative net income.
In the past year BHST has reported a negative cash flow from operations.
BHST had negative earnings in each of the past 5 years.
In the past 5 years BHST always reported negative operating cash flow.
BHST Yearly Net Income VS EBIT VS OCF VS FCFBHST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -2M -4M -6M -8M -10M

1.2 Ratios

BHST's Return On Assets of -66.58% is on the low side compared to the rest of the industry. BHST is outperformed by 85.71% of its industry peers.
BHST has a worse Return On Equity (-415.37%) than 82.86% of its industry peers.
Industry RankSector Rank
ROA -66.58%
ROE -415.37%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BHST Yearly ROA, ROE, ROICBHST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 200 -200

1.3 Margins

With a Gross Margin value of 54.00%, BHST is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
BHST's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for BHST so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.45%
GM growth 5YN/A
BHST Yearly Profit, Operating, Gross MarginsBHST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

0

2. Health

2.1 Basic Checks

BHST does not have a ROIC to compare to the WACC, probably because it is not profitable.
BHST has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BHST Yearly Shares OutstandingBHST Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 100M 200M 300M 400M
BHST Yearly Total Debt VS Total AssetsBHST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2M 4M 6M 8M 10M

2.2 Solvency

BHST has an Altman-Z score of -1.50. This is a bad value and indicates that BHST is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.50, BHST is not doing good in the industry: 88.57% of the companies in the same industry are doing better.
BHST has a Debt/Equity ratio of 2.58. This is a high value indicating a heavy dependency on external financing.
BHST has a worse Debt to Equity ratio (2.58) than 82.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.58
Debt/FCF N/A
Altman-Z -1.5
ROIC/WACCN/A
WACC8.63%
BHST Yearly LT Debt VS Equity VS FCFBHST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 -5M -10M

2.3 Liquidity

A Current Ratio of 0.80 indicates that BHST may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.80, BHST is doing worse than 82.86% of the companies in the same industry.
BHST has a Quick Ratio of 0.80. This is a bad value and indicates that BHST is not financially healthy enough and could expect problems in meeting its short term obligations.
BHST has a worse Quick ratio (0.48) than 88.57% of its industry peers.
Industry RankSector Rank
Current Ratio 0.8
Quick Ratio 0.48
BHST Yearly Current Assets VS Current LiabilitesBHST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 1M 2M 3M 4M 5M

More info and screens

7

3. Growth

3.1 Past

BHST shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -734.76%.
BHST shows a strong growth in Revenue. In the last year, the Revenue has grown by 111.68%.
BHST shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 217.48% yearly.
EPS 1Y (TTM)-734.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.51%
Revenue 1Y (TTM)111.68%
Revenue growth 3Y217.48%
Revenue growth 5YN/A
Sales Q2Q%101.88%

3.2 Future

BHST is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.77% yearly.
The Revenue is expected to grow by 88.58% on average over the next years. This is a very strong growth
EPS Next Y-4%
EPS Next 2Y31.18%
EPS Next 3Y31.77%
EPS Next 5YN/A
Revenue Next Year161.11%
Revenue Next 2Y107.4%
Revenue Next 3Y88.58%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BHST Yearly Revenue VS EstimatesBHST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
BHST Yearly EPS VS EstimatesBHST Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 0 0.2 -0.2 -0.4 -0.6 -0.8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BHST. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BHST. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BHST Price Earnings VS Forward Price EarningsBHST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BHST Per share dataBHST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as BHST's earnings are expected to grow with 31.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.18%
EPS Next 3Y31.77%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BHST!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOHARVEST SCIENCES INC

NASDAQ:BHST (8/7/2025, 4:30:02 PM)

8.0999

+0.2 (+2.53%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-27 2025-08-27
Inst Owners0.74%
Inst Owner ChangeN/A
Ins Owners17.79%
Ins Owner ChangeN/A
Market Cap140.37M
Analysts82.5
Price Target9.3 (14.82%)
Short Float %0.13%
Short Ratio1.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.3%
Min EPS beat(2)-43.84%
Max EPS beat(2)60.44%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-15.18%
Min Revenue beat(2)-29.7%
Max Revenue beat(2)-0.66%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.26
P/FCF N/A
P/OCF N/A
P/B 33.91
P/tB 33.91
EV/EBITDA N/A
EPS(TTM)-1.19
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS1.29
BVpS0.24
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -66.58%
ROE -415.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.45%
GM growth 5YN/A
F-Score4
Asset Turnover0.87
Health
Industry RankSector Rank
Debt/Equity 2.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 242.72%
Cap/Sales 12.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.8
Quick Ratio 0.48
Altman-Z -1.5
F-Score4
WACC8.63%
ROIC/WACCN/A
Cap/Depr(3y)257.83%
Cap/Depr(5y)N/A
Cap/Sales(3y)37.5%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-734.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.51%
EPS Next Y-4%
EPS Next 2Y31.18%
EPS Next 3Y31.77%
EPS Next 5YN/A
Revenue 1Y (TTM)111.68%
Revenue growth 3Y217.48%
Revenue growth 5YN/A
Sales Q2Q%101.88%
Revenue Next Year161.11%
Revenue Next 2Y107.4%
Revenue Next 3Y88.58%
Revenue Next 5YN/A
EBIT growth 1Y21.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year64.8%
EBIT Next 3Y58.05%
EBIT Next 5YN/A
FCF growth 1Y3.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.22%
OCF growth 3YN/A
OCF growth 5YN/A